Global sustainable development is currently facing the problem of insufficient integrated resources. The transformation of key technologies is urgently needed for economic and social development to higher quality. As one of the pillar industries in the 21st century, bio-industry has great development prospects in sustainable energy development, agricultural production, pharmaceutical R&D, environmental protection technology, technology manufacturing and professional services, and plays a significant role in solving the current socio-economic development conflicts.
JIN Yi, a biomedical expert and senior clinical monitor, is a senior expert engaged in biomedical clinical laboratory analysis in China. With rich experience in pharmaceutical analysis, he has been engaged in biopharmaceutical clinical work in national drug clinical trial bases, domestic well-known innovative drug clinical development, world-class biopharmaceutical R&D and other institutions, achieving professional achievements in the pharmaceutical field. Through the sharing of Mr. JIN Yi’s experience and his long-term observation of biopharmaceutical development at home and abroad, he expects to bring new insights to the cultivation of domestic biopharmaceutical professionals and the development of biopharmaceutical industry.
“I started working in the pharmaceutical field since I finished my studies, initially working in drug analysis at an influential pharmaceutical company in Nanjing, which focused its new drug development on gastrointestinal and central nervous drugs and had a very mature drug development and management system. Therefore, I was able to familiarize myself with the complete drug development and trial analysis process during this period, which enhanced my professionalism and provided sufficient preparation for my later work at the National Drug Clinical Trial Site of the Second Affiliated Hospital of Soochow University.” JIN Yi believes that biomedical research and development attaches great importance to the comprehensive quality of practitioners. The starting point of study is just to prepare for the beginning of the career. In order to achieve certain achievements in the field of biomedicine, a very solid professional foundation, mature practical ability and experience familiar with the overall process are required. In addition, highly conscious learning ability and innovation also play an important role. These abilities helped JIN Yi obtain the opportunity to engage in clinical trials at the National Drug Clinical Trial Base of the Second Affiliated Hospital of Soochow University and well-known biomedical research and development institutions at home and abroad.
In terms of the current development of biomedicine at home and abroad, Mr. JIN Yi drew his own opinions based on the medical information he mastered. “At present, the growth rate of the worldwide pharmaceutical market is still very outstanding. According to the statistics, we can know that the growth rate of the market is basically maintained in the range of 6%, and the economic scale has already exceeded two trillion dollars in recent years. However, in the actual competition of biomedicine market, mainly developed countries, especially the United States in the national strategy of the development of biotechnology planning and continuous scientific research investment has a key impact on the innovation and development of the United States biomedicine industry. According to the authoritative list of the world’s most innovative companies published in recent years, the United States won seven out of 10 places in 2018 and all of them in 2019, and the United States ranked first in the total number of high-quality biomedical papers and patents in recent years. It shows that the U.S. investment and R&D capabilities in biotech are really paying off.” Mr. JIN Yi also specifically mentioned the current situation of new drug research and development and generic drugs. “It is worth noting that the production of new drugs under the current biomedical technology update is mainly in major developed countries in Europe and the United States and Japan, South Korea and other countries in Asia. The R&D industry of new drugs in these countries has accumulated pharmaceutical patents, long-term industrial policies, advanced talent training methods, and technological innovation incentive mechanisms. Since 2013, it has maintained continuous growth, and even hundreds of new drugs can be added a year, accounting for most of the world’s output of new drug types. There is also a lot of potential for generic drugs in pharmaceutical research and development. Especially for developing countries, there are many obstacles to the independent research and development route of medicines. Developed countries have strict regulations on pharmaceutical patents, and it is easy for developing countries to be able to make progress in the field of medicine. Through the technological route of imitating generic drugs, it is a relatively convenient road for the pharmaceutical industry in developing countries to achieve a similar or even the same degree of efficacy as the original drug in terms of raw materials and formulas. However, in the field of new drug research and development, developing countries also need the accumulation of technology and professional talents.”
Referring to the observation of the development of biomedical industry in developed countries and several suggestions for the development of related industries in China, Mr. JIN Yi said: “In the analysis of international competitive advantages, the classic analysis – Michael Porter Diamond Model is often used, through which we can clearly understand the advantages and disadvantages of China in the international biomedical industry competition. China’s current biopharmaceutical industry scale and market demand to maintain a rapid growth pattern, marking the gradual utilization of the country’s huge development potential in the biopharmaceutical industry. In addition, the state stimulates social funds to invest in biomedical R&D with special programs, and the industrial system and regulatory system continue to be improved. Nowadays, China’s biopharmaceutical industry has made solid progress. However, there is still a certain gap in pharmaceutical production technology and R&D technology, such as in terms of diagnostic reagent varieties, which are not satisfactory compared with a large variety of diagnostic reagents in major developed countries. Therefore, I hope that China’s biopharmaceutical industry, under good national policies, can quickly realize industrial alliances, continuously increase research investment, improve research and innovation incentive mechanisms, enhance international technical exchanges, etc., and provide solid strength for the high-quality development of the China’s biopharmaceutical industry.” (Reporter: Sofia Wong)
